Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Ac-LKKTETQ-OH is a heptapeptide derived from thymosin beta-4, known for its regenerative and protective roles in various tissues
Oncologist 27(5):371-379, 2022
FOXO4-DRI (Proxofim) is a synthetic retro-inverso peptide designed to disrupt the interaction between FOXO4 transcription factor and p53
Tendon and Ligament Biology Chang et al
To, K., Cao, R., Yegiazaryan, A., Owens, J., Nguyen, T., Sasaninia, K., Vaughn, C., Singh, M., Truong, E., Medina, A., Avitia, E., Villegas, J., Pham, C., Sathananthan, A
US$ 22.61
US$ 21.80
US$ 21.29
US$ 22.37
